Treatment options for prehypertension

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension. RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure. SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.

Original languageEnglish (US)
Pages (from-to)250-255
Number of pages6
JournalCurrent opinion in nephrology and hypertension
Issue number3
StatePublished - May 2007


  • Angiotensin receptor blocker
  • Candesartan cilexetil
  • High normal blood pressure
  • Lifestyle modification
  • Prehypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology


Dive into the research topics of 'Treatment options for prehypertension'. Together they form a unique fingerprint.

Cite this